[go: up one dir, main page]

WO2001010841A3 - Fluorenderivate als integrin inhibitoren - Google Patents

Fluorenderivate als integrin inhibitoren Download PDF

Info

Publication number
WO2001010841A3
WO2001010841A3 PCT/EP2000/007153 EP0007153W WO0110841A3 WO 2001010841 A3 WO2001010841 A3 WO 2001010841A3 EP 0007153 W EP0007153 W EP 0007153W WO 0110841 A3 WO0110841 A3 WO 0110841A3
Authority
WO
WIPO (PCT)
Prior art keywords
integrin inhibitors
fluorene derivatives
disorders
arteriosclerosis
thrombosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/007153
Other languages
English (en)
French (fr)
Other versions
WO2001010841A2 (de
Inventor
Wolfgang Staehle
Simon Goodman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK140-2002A priority Critical patent/SK1402002A3/sk
Priority to EP00956284A priority patent/EP1208088A2/de
Priority to HK03101305.5A priority patent/HK1049006A1/zh
Priority to AU68286/00A priority patent/AU6828600A/en
Priority to PL00353054A priority patent/PL353054A1/xx
Priority to JP2001515308A priority patent/JP2003506439A/ja
Priority to BR0013083-4A priority patent/BR0013083A/pt
Priority to KR1020027000660A priority patent/KR20020012631A/ko
Priority to MXPA02001297A priority patent/MXPA02001297A/es
Priority to CA002380981A priority patent/CA2380981A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to HU0202464A priority patent/HUP0202464A3/hu
Publication of WO2001010841A2 publication Critical patent/WO2001010841A2/de
Publication of WO2001010841A3 publication Critical patent/WO2001010841A3/de
Priority to NO20020592A priority patent/NO20020592L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Verbindungen der Formel (I), worin R?1, R2, R3, R4, R5¿, m und n die in Anspruch 1 angegebene Bedeutung haben, sowie deren physiologisch unbedenklichen Salze und Solvate können als Integrin-Inhibitoren insbesondere zur Prophylaxe und Behandlung von Erkrankungen des Kreislaufs, bei Thrombose, Herzinfarkt, koronaren Herzerkrankungen, Arteriosklerose, Osteoporose, bei pathologischen Vorgängen, die durch Angiogenese unterhalten oder propagiert werden und in der Tumortherapie verwendet werden.
PCT/EP2000/007153 1999-08-07 2000-07-26 Fluorenderivate als integrin inhibitoren Ceased WO2001010841A2 (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MXPA02001297A MXPA02001297A (es) 1999-08-07 2000-07-26 Derivados del fluoreno.
HK03101305.5A HK1049006A1 (zh) 1999-08-07 2000-07-26 芴衍生物
AU68286/00A AU6828600A (en) 1999-08-07 2000-07-26 Fluorene derivatives
PL00353054A PL353054A1 (en) 1999-08-07 2000-07-26 Fluorene derivatives as integrin inhibitors
JP2001515308A JP2003506439A (ja) 1999-08-07 2000-07-26 フルオレン誘導体
BR0013083-4A BR0013083A (pt) 1999-08-07 2000-07-26 Derivados de fluorano
KR1020027000660A KR20020012631A (ko) 1999-08-07 2000-07-26 플루오렌 유도체
SK140-2002A SK1402002A3 (en) 1999-08-07 2000-07-26 Fluorene derivative, process for the preparation thereof and pharmaceutical composition comprising same
EP00956284A EP1208088A2 (de) 1999-08-07 2000-07-26 Fluorenderivate als integrininhibitoren
CA002380981A CA2380981A1 (en) 1999-08-07 2000-07-26 Fluorene derivatives
HU0202464A HUP0202464A3 (en) 1999-08-07 2000-07-26 Imidazolyl aminoalkyl fluorene derivatives, process for their preparation, pharmaceutical compositions containing them and their use
NO20020592A NO20020592L (no) 1999-08-07 2002-02-06 Fluorenderivater som integrininhibitorer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937394.9 1999-08-07
DE19937394A DE19937394A1 (de) 1999-08-07 1999-08-07 Fluorenderivate

Publications (2)

Publication Number Publication Date
WO2001010841A2 WO2001010841A2 (de) 2001-02-15
WO2001010841A3 true WO2001010841A3 (de) 2001-09-07

Family

ID=7917613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007153 Ceased WO2001010841A2 (de) 1999-08-07 2000-07-26 Fluorenderivate als integrin inhibitoren

Country Status (18)

Country Link
EP (1) EP1208088A2 (de)
JP (1) JP2003506439A (de)
KR (1) KR20020012631A (de)
CN (1) CN1368962A (de)
AR (1) AR025042A1 (de)
AU (1) AU6828600A (de)
BR (1) BR0013083A (de)
CA (1) CA2380981A1 (de)
CZ (1) CZ2002298A3 (de)
DE (1) DE19937394A1 (de)
HK (1) HK1049006A1 (de)
HU (1) HUP0202464A3 (de)
MX (1) MXPA02001297A (de)
NO (1) NO20020592L (de)
PL (1) PL353054A1 (de)
SK (1) SK1402002A3 (de)
WO (1) WO2001010841A2 (de)
ZA (1) ZA200201873B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101102808B1 (ko) * 2010-04-13 2012-01-05 윤태삼 라이저 인장 장치
US8574899B2 (en) 2010-12-22 2013-11-05 Vladimir B Serikov Methods for augmentation collection of placental hematopoietic stem cells and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015602A1 (en) * 1989-06-22 1990-12-27 Nova Pharmaceutical Corporation Pharmaceutical compositions and methods for treating inflammation
EP0675112A1 (de) * 1994-03-31 1995-10-04 Bristol-Myers Squibb Company Imidazol-enthaltende Farnesyl-Protein-Transferase-Inhibitoren
WO1997036862A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
DE19654483A1 (de) * 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanin-Derivate
EP0832883A1 (de) * 1996-09-26 1998-04-01 Eli Lilly And Company Tetra-Hydrobenzo(a)fluorenverbindungen und ihre Anwendungen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015602A1 (en) * 1989-06-22 1990-12-27 Nova Pharmaceutical Corporation Pharmaceutical compositions and methods for treating inflammation
EP0675112A1 (de) * 1994-03-31 1995-10-04 Bristol-Myers Squibb Company Imidazol-enthaltende Farnesyl-Protein-Transferase-Inhibitoren
WO1997036862A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
DE19654483A1 (de) * 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanin-Derivate
EP0832883A1 (de) * 1996-09-26 1998-04-01 Eli Lilly And Company Tetra-Hydrobenzo(a)fluorenverbindungen und ihre Anwendungen

Also Published As

Publication number Publication date
AR025042A1 (es) 2002-11-06
MXPA02001297A (es) 2004-07-16
NO20020592L (no) 2002-04-04
ZA200201873B (en) 2003-08-27
KR20020012631A (ko) 2002-02-16
CN1368962A (zh) 2002-09-11
HUP0202464A3 (en) 2003-02-28
SK1402002A3 (en) 2002-06-04
CA2380981A1 (en) 2001-02-15
AU6828600A (en) 2001-03-05
JP2003506439A (ja) 2003-02-18
NO20020592D0 (no) 2002-02-06
EP1208088A2 (de) 2002-05-29
BR0013083A (pt) 2002-04-23
DE19937394A1 (de) 2001-02-08
PL353054A1 (en) 2003-10-06
HUP0202464A2 (hu) 2002-12-28
HK1049006A1 (zh) 2003-04-25
WO2001010841A2 (de) 2001-02-15
CZ2002298A3 (cs) 2002-04-17

Similar Documents

Publication Publication Date Title
TW372232B (en) Phenylalanine derivatives
NO20010203L (no) Diacylhydrazinderivater som integrininhibitorer
NZ511927A (en) Phenylglycine derivatives
MY134783A (en) Rho-kinase inhibitors
WO2002076977A3 (en) Rho-kinase inhibitors
DE60324183D1 (en) Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
NO972892L (no) Bicykliske lavmolekylvekts-trombin-inhibitorer
BG105880A (en) Compounds useful as anti-inflammatory agents
WO2001064642A3 (en) Benzamides and related inhibitors of factor xa
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
TW200407326A (en) Pyrimido compounds having antiproliferative activity
WO2000055159A3 (en) Substituted aza-oxindole derivatives
FI913478A0 (fi) Diazinderivat.
TR199901962T2 (xx) Bisiklik amino asitler.
CA2348391A1 (en) Chromenone and chromanone derivatives as integrin inhibitors
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
MY133897A (en) N-(4-carb-amimidophenyl) glycineamide derivatives
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
WO2002018379A3 (en) 7-oxo pyridopyrimidines
NO308897B1 (no) Benzotiazin-dioksyder som endotelin-antagonister, fremgangsmÕter for fremstilling derav, farmasøytiske preparater omfattende forbindelsene, samt anvendelse av forbindelsene
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
NZ240481A (en) Aminosulphonyl urea derivatives and pharmaceutical compositions
BR0308195A (pt) Derivados de isoquinolina
NO20020131L (no) Diacylhydrazinderivater
WO2001010841A3 (de) Fluorenderivate als integrin inhibitoren

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000956284

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020027000660

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2002-298

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1402002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2380981

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001297

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 008114765

Country of ref document: CN

Ref document number: 10049053

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020027000660

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 68286/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/301/KOL

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2002 2002105512

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1200200222

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: PV2002-298

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000956284

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: PV2002-298

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000956284

Country of ref document: EP